Novo Nordisk to cap insulin prices in Minnesota settlement

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.
Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...
Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity: Bagsværd, Denmark Monday, January 27, 2025, 13:00 ...